Eli Lilly and Company and Incyte Corporation announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE).
Eli Lilly and Company and Incyte Corporation announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE).
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![Maak saaie content interessant: spelen met invalshoeken [3 tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/01/high-angle-shot-of-a-diverse-business-team-hands-p-2023-11-27-05-19-55-utc-1-80x60.jpg)